COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD
10/13
Positive
POSITIVE
Late
Rajter et al., Chest, doi:10.1016/j.chest.2020.10.009 (Peer Reviewed)
death, ↓46.0%, p=0.04 Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study)
Retrospective 280 hospitalized patients showing lower mortality with ivermectin (13.3% vs 24.5%), propensity matched odds ratio OR 0.47 [0.22-0.99], p=0.045.
10/9
Positive
POSITIVE
Late
Mahmud et al., Clinical Trial Results, NCT04523831 (Preprint)
no recov., ↓49.0%, p<0.004 Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection
RCT for ivermectin+doxycycline showing improvements in mortality, recovery, progression, and virological cure. There is no paper yet, results are reported on clinicaltrials.gov. 183 treatment and 180 control patients. Treatment delay is n..
9/24
Positive
POSITIVE
Late
Khan et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.08.007 (Letter)
death, ↓87.0%, p<0.05 Ivermectin treatment may improve the prognosis of patients with COVID-19
Retrospective 115 ivermectin patients and 133 control patients showing significantly lower death and faster viral clearance.
9/22
In Vitro
IN VITRO
N/A
Li et al., J. Cellular Physiology, doi:10.1002/jcp.30055 (Peer Reviewed)
Quantitative proteomics reveals a broad‐spectrum antiviral property of ivermectin, benefiting for COVID‐19 treatment
In Vitro study showing Ivermectin is a safe wide-spectrum antiviral against SARS-CoV-2, human papillomavirus (HPV), Epstein–Barr virus (EBV), and HIV. Authors note that the combination of ivermectin and other drugs might result in more f..
9/15
Review
REVIEW
Review
Jans et al., Cells 2020, 9:9, 2100, doi:10.3390/cells9092100 (Review) (Letter)
Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
Review of ivermectin as a host-directed broad-spectrum antiviral agent for a range of viruses, including SARS-CoV-2. Cell culture experiments show robust antiviral action towards HIV-1, dengue virus (DENV), Zika virus, West Nile virus, V..
9/3
Inconc.
INCONC.
Late
Podder et al., IMC J. Med. Science, 14:2, July 2020 (Peer Reviewed)
Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study
Small RCT with 32 ivermectin patients and 30 control patients. The mean recovery time after enrolment in the intervention arm was 5.31 ± 2.48 days vs. 6.33 ± 4.23 days in the control arm, p > 0.05. Negative PCR results were not signific..
8/28
Positive
POSITIVE
PEP
Shouman et al., NCT04422561 (Preprint)
cases, ↓91.3%, p=0.001 Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contacts with Patients of COVID-19
PEP trial for asymptomatic close contacts of COVID-19 patients, 203 ivermectin patients and 101 control patients. 7.4% of contacts developed COVID-19 in the ivermectin group vs. 58.4% in the control group, adjusted odds ratio OR 0.087, p ..
7/31
Inconc.
INCONC.
Late
Alam et al., Journal of Bangladesh College of Physicians and Surgeons, doi:10.3329/jbcps.v38i0.47512 (Peer Reviewed)
A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline
Case study of 100 patients treated with ivermectin and doxycycline, with no ICU admission, deaths, or serious side effects reported.
7/14
Inconc.
INCONC.
Early
Chowdhury et al., Research Square, doi:10.21203/rs.3.rs-38896/v1 (Preprint)
A Randomized Trial of Ivermectin-Doxycycline and Hydroxych loroquine-Azithromycin therapy on COVID19 patients
Small 116 patient RCT comparing Ivermectin-Doxycycline and HC Q+AZ, not showing a significant difference in time to PCR negative or symptom resolution. Time to symptomatic recovery was 5.93 days for Ivermectin-Doxycy..
7/8
Positive
POSITIVE
Late
Gorial et al., medRxiv, doi:10.1101/2020.07.07.20145979 (Preprint)
hosp. time, ↓42.0%, p<0.001 Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)
Small trial of hospitalized patients with 16 of 87 patients being treated with ivermectin showing a significantly lower mean hospital stay with ivermectin: 7.62 vs. 13.22 days, p=0.00005. 0 of 16 ivermectin patients died vs. 2 of 69 cont..
6/30
In Vitro
IN VITRO
N/A
Caly et al., Antiviral Research, doi:10.1016/j.antiviral.2020.104787 (Peer Reviewed)
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
In Vitro study showing that ivermectin is an inhibitor of SARS-CoV-2, with a single addition to Vero-hSLAM cells 2h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48h.
6/19
Theory
THEORY
Theory
Lehrer et al., In Vivo, 34:5, 3023-3026, doi:10.21873/invivo.12134 (Theory)
Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2
In silico analysis showing ivermectin docking which may interfere with the attachment of the spike to the human cell membrane.
6/12
Review
REVIEW
Review
Heiday et al., The Journal of Antibiotics, 73, 593–602, doi:10.1038/s41429-020-0336-z (Review) (Peer Reviewed)
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen
Review of the antimicrobial, antiviral, and anti-cancer properties of ivermectin. Antiviral effects have been reported for Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki For..


Please send us corrections, updates, comments.
Submit